Search
Search Results
-
Treatment patterns in stage III non‑small‑cell lung cancer patients: a population‑based study using German cancer registry data
PurposeLung cancer remains the leading cause of cancer-related mortality worldwide, mostly due to delayed diagnosis. The objective of this study is...
-
Longitudinal tracking of circulating rare events in the liquid biopsy of stage III–IV non-small cell lung cancer patients
In the United States, lung cancer is the second most common type of cancer with non-small cell lung cancer (NSCLC) encompassing around 85% of total...
-
Real-World Treatment Patterns and Survival Among Patients with Stage I–III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment
IntroductionApproximately half of patients with non-small cell lung cancer (NSCLC) present with early-stage disease at diagnosis. Real-world outcomes...
-
Post-radiotherapy stage III/IV non-small cell lung cancer radiomics research: a systematic review and comparison of CLEAR and RQS frameworks
BackgroundLung cancer, the second most common cancer, presents persistently dismal prognoses. Radiomics, a promising field, aims to provide novel...
-
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives
Management of stage II–III non-small cell lung cancer (NSCLC) has been dramatically revolutionized by studies testing the addition of immunotherapy...
-
A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
BackgroundStage III non-small cell lung cancer (NSCLC) is a heterogeneous disease with different subtypes, multidisciplinary teams-led management,...
-
Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy
BackgroundBaseline tumor size (BTS) is one of the prognostic factors of advanced non-small cell lung cancer (NSCLC) treated with immunotherapy....
-
Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer
BackgroundTo assess the predictive values of primary tumor FDG uptake for patients with inoperable stage III non-small cell lung cancer (NSCLC) after...
-
Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review
BackgroundNon-small cell lung cancer (NSCLC) is the predominant histological subtype of lung cancer and is the leading cause of cancer-related deaths...
-
Prognostic Significance of the Highest Mediastinal Lymph Node Involvement in Patients with Stage III-N2 Non-small Cell Lung Cancer
BackgroundHighest mediastinal lymph node (HMLN) involvement is a category of uncertain resection, yet the prognostic significance of HMLN involvement...
-
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study
This multicentre, two-arm, phase 2 study aimed to explore the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy or apatinib in...
-
Preoperative splenic area as a prognostic biomarker of early-stage non-small cell lung cancer
BackgroundThe correlation between the preoperative splenic area measured on CT scans and the overall survival (OS) of early-stage non-small cell lung...
-
The prognostic significance of right paratracheal lymph node dissection numbers in right upper lobe non-small cell lung cancer
BackgroundThe number of dissected lymph nodes is closely related to the prognosis of patients with non-small cell lung cancer. This study explored...
-
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
BackgroundAdjuvant immune checkpoint blockade (ICB) following chemoradiotherapy and adding ICB to chemotherapy have been key advances for stages...
-
Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review
BackgroundCurrently, immunotherapy is widely used in the treatment of various stages of non-small cell lung cancer. According to clinical experience...
-
Perioperative immunotherapy for resectable non-small-cell lung cancer
Lung cancer, of which non-small-cell lung cancer (NSCLC) is the most common type, is the leading cause of cancer-related deaths. Anatomic pulmonary...
-
Lung cancer-specific symptoms and fear of cancer recurrence among recurrence-free non-small cell lung cancer survivors
PurposeLung cancer survivors have more psychosocial problems, including depression and anxiety disorder, than other cancer survivors. Lung...
-
The additional radiotherapy to adjuvant chemotherapy improves the prognosis of stage III-N2 with highest mediastinal lymph node metastasis in non-small cell lung cancer
IntroductionThe benefits of adjuvant chemoradiation therapy (CRT) for heterogeneous pathological N2 (pN2) diseases remain unclear in non-small cell...
-
Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)
BackgroundApproximately 2 million new cases and 1.76 million deaths occur annually due to lung cancer, with the main histological subtype being...
-
Safety and efficacy of CT-guided percutaneous microwave ablation for stage I non-small cell lung cancer in patients with comorbid idiopathic pulmonary fibrosis
ObjectivesTo evaluate the safety and efficacy of microwave ablation (MWA) for stage I non-small cell lung cancer (NSCLC) in patients with idiopathic...
